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Healthcare rationing is high on the political and public agenda
in the United Kingdom. The English National Health Service
(NHS) is undergoing major restructuring aimed at improving
efficiency. From 2013, responsibility for commissioning NHS
services look set to shift from primary care trusts (PCTs) to
general practitioner (GP) commissioning consortiums, which
will also take over funding decisions on new clinical
interventions from the National Institute for Health and Clinical
Excellence (NICE). The coalition government’s comprehensive
spending review (which demands savings of £20bn (€23bn;
$32bn) over four years will take the NHS into a “fiscal ice age.”1
Patient and public involvement in decision making remains a
central part of the NHSmission and is a statutory responsibility
for commissioners of NHS care.2 However, although patient
and public participation in national and local decisions is widely
accepted, there is a lack of consensus on whether and how they
should be involved in rationing decisions at the individual level,3
and uncertainty about what involvement means in practice.
Tough decisions about individual
treatments
Rationing decisions involve hard choices. A particularly tough
subset of decisions comprise individual funding requests (IFRs)
for NHS services which fall outside agreed contracts between
local commissioning bodies and healthcare providers (table).
These requests are to fund an investigation or treatment as a
one-off for a particular patient even though it is not routinely
funded by the NHS. The request is submitted by the patient’s
doctor (consultant or general practitioner) and is usually
considered by a panel comprising PCT staff, local clinicians,
and (sometimes) lay people or their advocates. Some requests
(such as those for cancer or loss of vision) attract substantial
media attention, often articulated in the language of rescue
(patients are depicted as being denied treatment that could
prevent death or blindness).
Although their numbers are relatively small (about 26 000 cases
in England a year),4 IFRs have a substantial effect on patients
and their clinicians and take up a great deal of clinical and
managerial time (most PCTs deal with 100-200 requests a year,
but the range is 0-1000, with approval rates also varying from
0-100%).4-7
IFRs illustrate the conundrum of patient and public involvement
in financial, clinical, and ethical aspects of NHS resource
allocation and how all these aspects are interwoven. For
example, they highlight the tension between an individual rights
based and utilitarian (population, “greatest good”) ethical
position,8 and they raise questions about the different, often
conflicting roles of healthcare professionals, NHS managers,
and lay people as public servants and patient advocates.
IFR panels thus represent a forum in which the tension between
individual rights and population interests in healthcare rationing
is played out. By requiring increased NHS efficiency and
increased emphasis on patients’ rights and choices, the coalition
government has raised the stakes on both sides of this tension.
We anticipate that the work of IFR panels will be subject to
growing public scrutiny. Below we explore the ways in which
patients and the public can be involved in the process (box) and
review the (relatively sparse) evidence for current practice.
Bedside rationing
Medicine is traditionally depicted as a (knowledgeable) doctor
making practical and ethical judgments on behalf of a (less
knowledgeable) patient. Given the current emphasis on shared
decision making, should doctors tell patients that possibly useful
investigations or effective treatments exist that are not routinely
funded locally and discuss whether and how to present their
case to an IFR panel? Furthermore, should doctors discuss
treatments with their patients that others may consider effective
but they do not? Empirical studies of patients’ reactions to
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How patients and the public are involved in individual healthcare rationing decisions
• A patient’s doctor may share information, seek the patient’s opinion, or invite shared decision making before making
a request for individual funding
• Once a request has been submitted, the patient may be included in some or all of its processes (eg, copied into
correspondence or invited to be represented at or attend the meeting)
• Members of the public may be included in the panel (lay members)
• Patient organisations may help patients prepare their case for funding and occasionally help bring such cases to
judicial review
“bedside” rationing decisions in relation to their own healthcare
are few. One found that most patients considered implicit
rationing paternalistic and disempowering; they wanted doctors
to be explicit and transparent about such decisions, but not all
perceived their doctor to be so.9 10
In 2007, Marcus argued that patients had a right to know about
all available interventions and doctors had a duty to share such
knowledge.11 Holt has argued that “rationing by ignorance”
denies patients their rights to “freedom of thought” (the right
to know the truth), “freedom of speech” (the right to be angry
and say so), and “creative problem solving” (for example, to
purchase treatment privately or negotiate with a drug company).
The UK’s statutory regulator of medical practice, the General
Medical Council, recommends that doctors inform patients of
all appropriate treatment options to meet their clinical needs,
including “any treatments that you believe have greater potential
benefit for the patient than those you or your organisation can
offer.”12
This guidance is in line with an increasing consensus within
academic debate that explicit and systematic “bedside” rationing
is preferable to the implicit and unsystematic rationing that has
historically been the norm. 13 Others argue that doctors have a
“responsibility beyond the patient” to take account of the
constrained financial budgets within which they have to make
clinical decisions, and that the uncertain and time consuming
individual funding process may cause harm—for example, the
emotional effect of patients knowing about a treatment for which
they must struggle and may not eventually receive.9 14 Almost
one third of oncologists in one survey said they did not discuss
unfunded drugs with their patients.4 A study of general
practitioners found a considerable gap between the principle of
explicitness and reported practice and tension between their role
as patient advocate and their wider responsibilities for budgets,
populations, and society in general.3
Much research has been undertaken on healthcare rationing at
national and PCT levels, but there is surprisingly little detailed
research on bedside rationing decisions. We do not know, for
example, how clinicians internalise and take account of resource
constraints in their clinical judgments or “the extent to which
this results in the denial of potentially beneficial treatment
[rather than] a sensible reluctance to engage in heroic medicine
regardless of the cost.”1
Should patients be allowed to attend IFR
panels?
Some IFR panels do not allow patients or the referring clinician
to make direct representations. Others identify patient input,
usually in writing and occasionally in person, as a feature of
good practice. One pioneering PCT reports that the benefits of
direct patient representation include (for patients) reassurance
that their case is being taken seriously and (for the panel)
clarification of details and greater awareness of the person about
whom the decision is being made.15 Set against these benefits,
one of the few empirical studies of patients’ experiences of
rationing decisions reported that those who had attended IFR
panels found it difficult and sometimes distressing.9 And for
some critics, patient representation risks pulling panel members
away from rational decisionmaking towards an emotional, “rule
of rescue” response,16 although some ethicists believe this is
morally justified in some cases.16 17
Although IFR panels are not legally required to be open to
patients and the public, the NHS constitution seems to promise
patients the right of access: “You have the right to be involved
in discussions and decisions about your healthcare, and be given
information to enable you to do this.”18 Some argue that this
increased emphasis on an individual’s right to a voice may erode
healthcare purchasers’ fortitude to consider the complex issues
of opportunity costs and community interests, with planned
expenditure being diverted to individual cases.19 Thus, Newdick
argues, an individualised, consumerist model of care comes to
be privileged over the notion of social citizenship, and the needs
of individuals with the capacity to express their rights
(sometimes helped by drug companies) win over the needs of
patients less able to do so.8
Should IFR panels include lay people?
As the debate about rationing has progressed beyond an early
naive faith in the ability of evidence based medicine and
economics to tell us what to do when faced with complex
rationing decisions,20 so attention has turned to the necessary
conditions and procedures for fair and reasonable decision
making—namely, transparency, accountability, and broad
stakeholder involvement.21 Involvement of lay people is seen
as desirable because it potentially improves both quality and
legitimacy of decisions.22 NHS policy guidance uses the term
“lay involvement” frequently, but we have been unable to find
a definition, explanation, or justification of this term within
policy documents. In the case of IFR panels, there is explicit
advice about how panels should be constituted, what processes
they should follow, and how best to make “rational”
decisions,23 24 but advice on lay involvement is provided only
in the most general and abstract terms: “PCTs may . . . wish to
consider lay membership and the potential value of individuals
attending with ‘observer’ status.”24 There is no discussion of
laymembers’ role, who individuals with “observer status” might
be, or what value they potentially bring. Guidance on the new
Cancer Drug Fund (which adds an additional layer of complexity
to IFR decisions) contains no reference to lay membership.
In a 2008 Department of Health survey, one third of IFR panels
included “patients/advocacy representatives” but most of these
were PCT “patient advocacy leads” (that is, PCT staff), and
only two of the 130 PCTs reported having “lay members” on
their panels.5 In 2011, IFR panels increasingly seek (and some
formally include) lay members (voting or non-voting), but
considerable variation remains (JR and TG, unpublished data).
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We could find no published research on what and how lay
members contribute to decision making; what if any support
and training is available to them; or how variation in practice
is justified in local policies. Given the limited evidence base,
PCTs are vulnerable to accusations that lay members’
involvement in IFR decisions may not merely be tokenistic but
used (in some circumstances at least) to give an appearance of
democracy to difficult and unpopular rationing decisions.25 26
In studies of public views about involvement in healthcare
rationing, many people were keen to participate in decisions
about overall service priorities but most preferred to leave
decisions about individual patients to health professionals, whom
they viewed as having the appropriate knowledge, skills,
qualifications, and experience (including the ability to deal with
the emotional impact of the decision).1 26 27 28 Lack of public
appetite for involvement in IFRs has been attributed to
reluctance to confront the “disutility” (adverse effects) from
denying treatment or to acknowledge that constraints on health
services are necessary.29 30
The limited empirical research findings and polarised opinions
about lay representatives on rationing panels raise more
questions than they answer. Who do they represent, and for
whom do they speak?What is the value of the “common sense”
and “life experience” that they are said to bring to the table?22
Howwell equipped are they (and indeed non-specialist clinicians
andmanagers) to cope with the complexity of the science under
discussion?31 How and by whom should they be selected and
managed and have their performance evaluated?What measures
are needed to ensure that the lay voice is not marginalised or
dismissed? What can we learn from PCTs that have pioneered
approaches to working with lay people?
Rationing and reform
This paper is not intended to offer guidance on how to involve
patients and the public in individual NHS funding decisions but
to highlight the gaps in evidence and ethical controversies in
order to open up debate on this topic. Rhetorical slogans like
“No decision about us without us” appeal to widely shared
norms and values of transparency and patient centredness. But
patient and public involvement in rationing decisions is both
practically and ethically complex and may or may not be in the
best interests of the sick or dying patient. The UK national
cancer director has called for specific training for clinicians in
this particularly difficult aspect of doctor-patient
communication,4 and it is now addressed in the Department of
Health advanced communication skills training programme.
As we move rapidly towards a restructured NHS in which,
according to the government, decision making will be “in the
hands of professionals and patients,”2 the power dynamic in
healthcare rationing is set to shift significantly with worrying
potential consequences. General practitioners, in taking on the
work of PCTs in telling patients which treatments the NHS can
and cannot afford, may come to embody and enact the tensions
implicit in the new NHS structures—perhaps by taking sides
against one another in individual versus collective
responsibilities. Furthermore, as escalating financial pressures,
the lifting of the mandatory status of NICE technology appraisal
guidance, government promotion of patient choice, and an
increasingly competitive market combine to make it harder for
local health organisations to achieve rational commissioning,
local variation in access to certain treatments and contested
“exceptional” cases may increase. This could make patient
involvement in NHS rationing decisions more complex, more
adversarial, and more polarised towards the information rich.
Involving patients and the public in carefully controlled, small
scale discussions about individual funding requests (democratic
deliberation) is no substitute for the urgent public debate
(deliberative democracy) that is needed on how and where we
should draw the boundaries around publicly funded healthcare.32
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Table
Table 1| Examples of treatments that attract NHS funding in some cases but not others, typically after individual funding requests
ExamplesDescriptorType
Dasatinib for chronic myeloid leukaemiaHigh cost drugs and other interventions not yet appraised by
NICE
New treatments
Ranibizumab for wet age related macular degeneration (until approved
by NICE in 2011)
Surgical interventions such as trans-catheter aortic valve implantation
or endovascular fenestrated aortic stents for suprarenal aortic aneurysm
Bevacizumab for wet age related macular degenerationUse of approved interventions outside defined clinical criteriaTreatments outside NICE
guidance
Sorafenib for liver cancerTreatments rejected by NICE
Breast modification surgery, bariatric surgery, inpatient treatment for
chronic fatigue syndrome, and inpatient therapy for eating disorders in
children
PCTs have drawn up lists of treatments they no longer routinely
fund. They must, however, give consideration to the funding
of “exceptional” cases
Low priority treatments
Treatment of angiosarcomasMedical conditions or clinical presentations for which the PCT
has no policy (and no contract with a provider) because they
are rare
Rare conditions
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